Article Text

Download PDFPDF
Gynecologic Cancer InterGroup (GCIG) Consensus Review: Uterine and Ovarian Leiomyosarcomas
  1. Martee L. Hensley, MD, MSc*,
  2. Brigitte A. Barrette, MD,
  3. Klaus Baumann, MD,
  4. David Gaffney, MD, PhD§,
  5. Anne L. Hamilton, MD,
  6. Jae-Weon Kim, MD, PhD,
  7. Johanna U. Maenpaa, MD, PhD#,
  8. Patricia Pautier, MD**,
  9. Nadeem Ahmad Siddiqui, MD, PhD,,
  10. Anneke M. Westermann, MD, PhD, and
  11. Isabelle Ray-Coquard, MD, PhD§§
  1. *Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY;
  2. Mayo Clinic, Rochester, MN, GOG;
  3. Gynäkologische Endokrinologie und Onkologie Universitätsklinikum Gießen und Marburg GmbH, AGO;
  4. §Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah, Salt Lake City, UT, RTOG;
  5. Peter MacCallum Cancer Centre, Royal Women’s Hospital, University of Melbourne, Melbourne, Australia, ANZOG;
  6. Seoul National University College of Medicine, KGOG;
  7. #University of Tampere, Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland, NSGO;
  8. **Institut Gustave-Roussy, Villejuif, France, GINECO;
  9. ††NHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, Glasgow, Scotland, SGCTG;
  10. ‡‡Academic Medical Center, Amsterdam, Netherlands, DGOG;
  11. §§Centre Léon Bérard, Lyon, GINECO.
  1. Address correspondence and reprint requests to Martee L. Hensley, MD, Gynecologic Medical Oncology, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY, 300 E 66th St, Office 1355, Memorial Sloan Kettering Cancer Center, New York, NY 10065.

Abstract

Objectives The Gynecologic Cancer InterGroup aimed to provide an overview of uterine and ovarian leiomyosarcoma management.

Methods Published articles and author experience were used to draft management overview. The draft manuscript was circulated to international members of the Gynecologic Cancer InterGroup for review and comment, and appropriate revisions were made.

Results The approach to management of uterine and ovarian leiomyosarcoma management is reviewed.

Conclusions Uterine and ovarian leiomyosarcomas are rare and aggressive cancers that require specialized expertise for optimal management.

  • Uterine leiomyosarcoma
  • Ovarian leiomyosarcoma
  • Gynecologic Cancer InterGroup

Statistics from Altmetric.com

Footnotes

  • Financial disclosures: AL Hamilton served on the advisory board for GlaxoSmithKline. J. Maenpaa received grant funding and payment for lectures from Roche Finland, serves on the board for Roche Finland and MSD Finland, has acted as a consultant for Amgen Nordic and Janssen Cilag Finland, and has received meeting expense funding from LeoPharma, Janssen, and Sandoz. P. Pautier served on the advisory board of Pharmamar Laboratory.

  • The remaining authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.